The PROGRESS study: Rationale and design

Bruce Neal, Stephen MacMahon, Marie Germain Bousser, John Chalmers, Jeffrey Cutler, Geoffrey Donnan, Lennart Hansson, Stephen Harrap, Liu Lisheng, Stephen MacMahon, Giuseppe Mancia, Joel Menard, Teruo Omae, John Reid, Anthony Rodgers

Research output: Contribution to journalArticle

Abstract

Rationale: Patients with a history of cerebrovascular disease have a very high risk of stroke, and usual levels of both systolic and diastolic blood pressure are directly and continuously associated with this risk. Trials of blood pressure lowering in patients with transient ischaemic attacks or stroke have been too small to reliably detect the effects on stroke risk of the modest blood pressure reductions achieved. Objectives: The primary objective of PROGRESS is to determine precisely the effects of blood pressure reduction with an angiotensin converting enzyme (ACE) inhibitor-based regimen on the stroke risk in patients with a history of transient ischaemic attacks or minor stroke. Design: The study is a randomized, double-blind, placebo-controlled clinical trial. Before randomization, there is a 4-week run-in phase on open-label ACE inhibitor treatment. The scheduled duration of treatment and follow-up is 4-5 years. Setting: The study will be conducted in collaborating clinical centres in Australia, Belgium, the People’s Republic of China, France, Italy, Japan, New Zealand, Sweden and the United Kingdom. Patients: The study will involve 6000 patients with a history of transient ischaemic attacks or stroke (ischaemic or haemorrhagic) in the past 5 years. To be eligible patients should have no definite indication for or contra-indication to treatment with an ACE inhibitor and no disability likely to prevent regular attendance at study clinics. Interventions: Study treatment will comprise perindopril and indapamide or matching placebos for patients without an indication for or contra-indication to treatment with a diuretic, perindopril alone or matching placebo for all other patients. Study outcomes: The primary study outcome is total strokes and secondary outcomes include fatal or disabling strokes, total major cardiovascular events, cardiovascular deaths, cognitive function and dementia, and disability and dependency.

Original languageEnglish
Pages (from-to)1869-1873
Number of pages5
JournalJournal of Hypertension
Volume13
Issue number12
Publication statusPublished - 1995

Fingerprint

Stroke
Blood Pressure
Transient Ischemic Attack
Angiotensin-Converting Enzyme Inhibitors
Perindopril
Placebos
Outcome Assessment (Health Care)
Indapamide
Therapeutics
Cerebrovascular Disorders
Fatal Outcome
Belgium
Controlled Clinical Trials
Random Allocation
New Zealand
Diuretics
Sweden
Cognition
Italy
France

Keywords

  • Angiotensin converting enzyme inhibitors
  • Cardiovascular events
  • Cognitive function
  • Dementia
  • Ischaemia
  • Stroke

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Internal Medicine
  • Endocrinology

Cite this

Neal, B., MacMahon, S., Bousser, M. G., Chalmers, J., Cutler, J., Donnan, G., ... Rodgers, A. (1995). The PROGRESS study: Rationale and design. Journal of Hypertension, 13(12), 1869-1873.

The PROGRESS study : Rationale and design. / Neal, Bruce; MacMahon, Stephen; Bousser, Marie Germain; Chalmers, John; Cutler, Jeffrey; Donnan, Geoffrey; Hansson, Lennart; Harrap, Stephen; Lisheng, Liu; MacMahon, Stephen; Mancia, Giuseppe; Menard, Joel; Omae, Teruo; Reid, John; Rodgers, Anthony.

In: Journal of Hypertension, Vol. 13, No. 12, 1995, p. 1869-1873.

Research output: Contribution to journalArticle

Neal, B, MacMahon, S, Bousser, MG, Chalmers, J, Cutler, J, Donnan, G, Hansson, L, Harrap, S, Lisheng, L, MacMahon, S, Mancia, G, Menard, J, Omae, T, Reid, J & Rodgers, A 1995, 'The PROGRESS study: Rationale and design', Journal of Hypertension, vol. 13, no. 12, pp. 1869-1873.
Neal B, MacMahon S, Bousser MG, Chalmers J, Cutler J, Donnan G et al. The PROGRESS study: Rationale and design. Journal of Hypertension. 1995;13(12):1869-1873.
Neal, Bruce ; MacMahon, Stephen ; Bousser, Marie Germain ; Chalmers, John ; Cutler, Jeffrey ; Donnan, Geoffrey ; Hansson, Lennart ; Harrap, Stephen ; Lisheng, Liu ; MacMahon, Stephen ; Mancia, Giuseppe ; Menard, Joel ; Omae, Teruo ; Reid, John ; Rodgers, Anthony. / The PROGRESS study : Rationale and design. In: Journal of Hypertension. 1995 ; Vol. 13, No. 12. pp. 1869-1873.
@article{b6053919a3474a3ba32d13972c0198f4,
title = "The PROGRESS study: Rationale and design",
abstract = "Rationale: Patients with a history of cerebrovascular disease have a very high risk of stroke, and usual levels of both systolic and diastolic blood pressure are directly and continuously associated with this risk. Trials of blood pressure lowering in patients with transient ischaemic attacks or stroke have been too small to reliably detect the effects on stroke risk of the modest blood pressure reductions achieved. Objectives: The primary objective of PROGRESS is to determine precisely the effects of blood pressure reduction with an angiotensin converting enzyme (ACE) inhibitor-based regimen on the stroke risk in patients with a history of transient ischaemic attacks or minor stroke. Design: The study is a randomized, double-blind, placebo-controlled clinical trial. Before randomization, there is a 4-week run-in phase on open-label ACE inhibitor treatment. The scheduled duration of treatment and follow-up is 4-5 years. Setting: The study will be conducted in collaborating clinical centres in Australia, Belgium, the People’s Republic of China, France, Italy, Japan, New Zealand, Sweden and the United Kingdom. Patients: The study will involve 6000 patients with a history of transient ischaemic attacks or stroke (ischaemic or haemorrhagic) in the past 5 years. To be eligible patients should have no definite indication for or contra-indication to treatment with an ACE inhibitor and no disability likely to prevent regular attendance at study clinics. Interventions: Study treatment will comprise perindopril and indapamide or matching placebos for patients without an indication for or contra-indication to treatment with a diuretic, perindopril alone or matching placebo for all other patients. Study outcomes: The primary study outcome is total strokes and secondary outcomes include fatal or disabling strokes, total major cardiovascular events, cardiovascular deaths, cognitive function and dementia, and disability and dependency.",
keywords = "Angiotensin converting enzyme inhibitors, Cardiovascular events, Cognitive function, Dementia, Ischaemia, Stroke",
author = "Bruce Neal and Stephen MacMahon and Bousser, {Marie Germain} and John Chalmers and Jeffrey Cutler and Geoffrey Donnan and Lennart Hansson and Stephen Harrap and Liu Lisheng and Stephen MacMahon and Giuseppe Mancia and Joel Menard and Teruo Omae and John Reid and Anthony Rodgers",
year = "1995",
language = "English",
volume = "13",
pages = "1869--1873",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - The PROGRESS study

T2 - Rationale and design

AU - Neal, Bruce

AU - MacMahon, Stephen

AU - Bousser, Marie Germain

AU - Chalmers, John

AU - Cutler, Jeffrey

AU - Donnan, Geoffrey

AU - Hansson, Lennart

AU - Harrap, Stephen

AU - Lisheng, Liu

AU - MacMahon, Stephen

AU - Mancia, Giuseppe

AU - Menard, Joel

AU - Omae, Teruo

AU - Reid, John

AU - Rodgers, Anthony

PY - 1995

Y1 - 1995

N2 - Rationale: Patients with a history of cerebrovascular disease have a very high risk of stroke, and usual levels of both systolic and diastolic blood pressure are directly and continuously associated with this risk. Trials of blood pressure lowering in patients with transient ischaemic attacks or stroke have been too small to reliably detect the effects on stroke risk of the modest blood pressure reductions achieved. Objectives: The primary objective of PROGRESS is to determine precisely the effects of blood pressure reduction with an angiotensin converting enzyme (ACE) inhibitor-based regimen on the stroke risk in patients with a history of transient ischaemic attacks or minor stroke. Design: The study is a randomized, double-blind, placebo-controlled clinical trial. Before randomization, there is a 4-week run-in phase on open-label ACE inhibitor treatment. The scheduled duration of treatment and follow-up is 4-5 years. Setting: The study will be conducted in collaborating clinical centres in Australia, Belgium, the People’s Republic of China, France, Italy, Japan, New Zealand, Sweden and the United Kingdom. Patients: The study will involve 6000 patients with a history of transient ischaemic attacks or stroke (ischaemic or haemorrhagic) in the past 5 years. To be eligible patients should have no definite indication for or contra-indication to treatment with an ACE inhibitor and no disability likely to prevent regular attendance at study clinics. Interventions: Study treatment will comprise perindopril and indapamide or matching placebos for patients without an indication for or contra-indication to treatment with a diuretic, perindopril alone or matching placebo for all other patients. Study outcomes: The primary study outcome is total strokes and secondary outcomes include fatal or disabling strokes, total major cardiovascular events, cardiovascular deaths, cognitive function and dementia, and disability and dependency.

AB - Rationale: Patients with a history of cerebrovascular disease have a very high risk of stroke, and usual levels of both systolic and diastolic blood pressure are directly and continuously associated with this risk. Trials of blood pressure lowering in patients with transient ischaemic attacks or stroke have been too small to reliably detect the effects on stroke risk of the modest blood pressure reductions achieved. Objectives: The primary objective of PROGRESS is to determine precisely the effects of blood pressure reduction with an angiotensin converting enzyme (ACE) inhibitor-based regimen on the stroke risk in patients with a history of transient ischaemic attacks or minor stroke. Design: The study is a randomized, double-blind, placebo-controlled clinical trial. Before randomization, there is a 4-week run-in phase on open-label ACE inhibitor treatment. The scheduled duration of treatment and follow-up is 4-5 years. Setting: The study will be conducted in collaborating clinical centres in Australia, Belgium, the People’s Republic of China, France, Italy, Japan, New Zealand, Sweden and the United Kingdom. Patients: The study will involve 6000 patients with a history of transient ischaemic attacks or stroke (ischaemic or haemorrhagic) in the past 5 years. To be eligible patients should have no definite indication for or contra-indication to treatment with an ACE inhibitor and no disability likely to prevent regular attendance at study clinics. Interventions: Study treatment will comprise perindopril and indapamide or matching placebos for patients without an indication for or contra-indication to treatment with a diuretic, perindopril alone or matching placebo for all other patients. Study outcomes: The primary study outcome is total strokes and secondary outcomes include fatal or disabling strokes, total major cardiovascular events, cardiovascular deaths, cognitive function and dementia, and disability and dependency.

KW - Angiotensin converting enzyme inhibitors

KW - Cardiovascular events

KW - Cognitive function

KW - Dementia

KW - Ischaemia

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=0029560114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029560114&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029560114

VL - 13

SP - 1869

EP - 1873

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 12

ER -